GoodRx Holdings, Inc. (GDRX) Q3 2024 Earnings Call Transcript
While the top- and bottom-line numbers for GoodRx (GDRX) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.06 per share a year ago.
Beyond analysts' top -and-bottom-line estimates for GoodRx (GDRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
Smaller pharmacies are accusing GoodRx and CVS of colluding to suppress generic prescription drug reimbursements. As Reuters reported Tuesday (Nov. 5), drug coupon aggregator GoodRx and a pair of pharmacy benefit managers (PBMs) — CVS's Caremark unit and Express Scripts — have all been named in at least three lawsuits by independent pharmacies.
Today, we are circling back on GoodRx Holdings, which offers a platform for comparing prescription drug prices. The company also enables their customers to benefit from negotiated prices through GoodRx codes that are used to save money on prescriptions. The stock has a bit of a rocky ride since forward guidance disappointed following second-quarter results.
Investors interested in stocks from the Medical Services sector have probably already heard of Elevance Health (ELV) and GoodRx Holdings, Inc. (GDRX). But which of these two stocks presents investors with the better value opportunity right now?
It was a mixed bag of growth and challenges for digital healthcare platform GoodRx during the second quarter. In reporting its second-quarter results Thursday (Aug. 8), GoodRx said monthly active users (MACs) rose 8%, contributing to a 7% rise in prescription transactions revenue, which totaled $146.7 million.
GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Aubrey Reynolds - Director of Investor Relations Scott Wagner - Interim Chief Executive Officer Karsten Voermann - Chief Financial Officer Mike Walsh - President & EVP, Prescription Marketplace Conference Call Participants Charles Rhyee - TD Cowen Lisa Gill - JPMorgan John Ransom - Raymond James Stephanie Davis - Barclays Jailendra Singh - Truist Securities Scott Schoenhaus - KeyBanc Stan Berenshteyn - Wells Fargo Securities Kevin Caliendo - UBS Allen Lutz - Bank of America Daniel Grosslight - Citi Jack Wallace - Guggenheim Securities George Hill - Deutsche Bank Operator Ladies and gentlemen, thank you for standing by, and welcome to the Rx Second Quarter 2024 Earnings Call. As a reminder, today's conference call is being recorded.
Prescription savings platform GoodRx Holdings Inc. GDRX reported second-quarter revenue of $200.61 million, up 6% year over year, almost in line with the consensus of $200.4 million.
Although the revenue and EPS for GoodRx (GDRX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.